By Stephen Nakrosis 

Gilead Sciences Inc. said Monday it named Mark Genovese to oversee the clinical development of its investigational portfolio of treatments for inflammatory conditions.

Dr. Genovese comes to Gilead from Stanford University, where he was on the faculty for more than 21 years and most recently served as the James W. Raitt Professor of Medicine and Clinical Chief in the Division of Immunology and Rheumatology, the company said.

Dr. Genovese, who was named as the company's SVP, Inflammation, will have responsibility "for the company's fibrosis clinical research programs including nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis and systemic sclerosis," the company said.

Gilead said it is expanding its work in the field of inflammatory diseases, and added it has filed for regulatory approval in the U.S., Europe and Japan "of a potential treatment for rheumatoid arthritis, which, if approved, would be the company's first medicine to treat an inflammatory disease."


--Write to Stephen Nakrosis at


(END) Dow Jones Newswires

June 01, 2020 18:54 ET (22:54 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.